| Oxidative stress in the tumor microenvironment and its relevance to cancer immunotherapy NS Aboelella, C Brandle, T Kim, ZC Ding, G Zhou Cancers 13 (5), 986, 2021 | 148 | 2021 |
| Indomethacin-induced oxidative stress enhances death receptor 5 signaling and sensitizes tumor cells to adoptive T-cell therapy NS Aboelella, C Brandle, O Okoko, MY Gazi, ZC Ding, H Xu, G Gorman, ... Journal for Immunotherapy of Cancer 10 (7), 2022 | 8 | 2022 |
| Molecular and epigenetic mechanisms by which STAT5 regulates polyfunctionality in antitumor CD4+ T cells. O Okoko, MY Gazi, M Kehinde-Ige, X Wang, C Brandle, H Shi, G Zhou The Journal of Immunology 212 (1_Supplement), 0048_5430-0048_5430, 2024 | | 2024 |
| ADT-030 is a novel dual-acting RAS/β-catenin inhibitor that potentiates antitumor immunity MY Gazi, O Okoko, X Wang, C Brandle, X Chen, K Fadlalla, A Keeton, ... Cancer Research 84 (6_Supplement), 2459-2459, 2024 | | 2024 |
| Repurposing NSAIDs for chemo-immunotherapy: mechanisms beyond COX inhibition OD Okoko, MY Gazi, X Wang, C Brandle, M Kehinde-Ige, GA Piazza, ... Cancer Research 83 (7_Supplement), 6333-6333, 2023 | | 2023 |
| A novel dual-acting RAS/β-catenin inhibitor activates antitumor immunity to potentiate cancer immunotherapy MY Gazi, O Okoko, X Wang, C Brandle, Z Ding, A Mitra, ... Cancer Research 83 (7_Supplement), 478-478, 2023 | | 2023 |
| Antitumor CD4+ T cells reprogram tumor metabolism to drive progressive tumor regression C Brandle, OD Okoko, MY Gazi, X Wang, M Kehinde-Ige, H Shi, G Zhou Cancer Research 83 (7_Supplement), 268-268, 2023 | | 2023 |
| The antitumor activity and immumodulatory effect of a novel phosphodiesterase 10 inhibitor MY Gazi, C Brandle, O Okoko, X Chen, A Keeton, Y Maxuitenko, G Piazza, ... Cancer Research 82 (12_Supplement), 5322-5322, 2022 | | 2022 |
